MAPT and Alzheimer disease: This endogenous inhibitor does not target all lysosomal proteases, implicated in Alzheimer’s disease, it does not impact the activity of Cathepsin D, which has recently been suggested to have a role in disease development via its function in amyloid-β and tau clearance [24].